DE602005020076D1 - Herstellung von TNFR-Fc - Google Patents

Herstellung von TNFR-Fc

Info

Publication number
DE602005020076D1
DE602005020076D1 DE602005020076T DE602005020076T DE602005020076D1 DE 602005020076 D1 DE602005020076 D1 DE 602005020076D1 DE 602005020076 T DE602005020076 T DE 602005020076T DE 602005020076 T DE602005020076 T DE 602005020076T DE 602005020076 D1 DE602005020076 D1 DE 602005020076D1
Authority
DE
Germany
Prior art keywords
tnfr
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005020076T
Other languages
English (en)
Inventor
Denis Drapeau
Yen-Tung Luan
James R Mercer
Wenge Wang
Daniel R Lasko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Research Ireland Ltd
Original Assignee
Wyeth Research Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35500648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602005020076(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Research Ireland Ltd filed Critical Wyeth Research Ireland Ltd
Publication of DE602005020076D1 publication Critical patent/DE602005020076D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/95—Protein-free medium and culture conditions
DE602005020076T 2004-08-27 2005-08-26 Herstellung von TNFR-Fc Active DE602005020076D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60537904P 2004-08-27 2004-08-27

Publications (1)

Publication Number Publication Date
DE602005020076D1 true DE602005020076D1 (de) 2010-04-29

Family

ID=35500648

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602005020076T Active DE602005020076D1 (de) 2004-08-27 2005-08-26 Herstellung von TNFR-Fc
DE602005017285T Active DE602005017285D1 (de) 2004-08-27 2005-08-26

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE602005017285T Active DE602005017285D1 (de) 2004-08-27 2005-08-26

Country Status (38)

Country Link
US (1) US7300773B2 (de)
EP (2) EP1992697B1 (de)
JP (3) JP2008511330A (de)
KR (1) KR100988451B1 (de)
CN (2) CN102876761A (de)
AR (2) AR050537A1 (de)
AT (2) ATE461285T1 (de)
AU (1) AU2005280036B2 (de)
BR (1) BRPI0514694B8 (de)
CA (1) CA2578138C (de)
CL (1) CL2017000577A1 (de)
CR (2) CR8998A (de)
CY (2) CY1109721T1 (de)
DE (2) DE602005020076D1 (de)
DK (2) DK1781802T3 (de)
EC (1) ECSP077354A (de)
EG (1) EG26922A (de)
ES (2) ES2335518T3 (de)
GT (2) GT200500234A (de)
HK (2) HK1099941A1 (de)
HN (1) HN2005000485A (de)
HR (2) HRP20100011T1 (de)
IL (1) IL181588A (de)
MX (1) MX2007002381A (de)
MY (1) MY137803A (de)
NO (1) NO344785B1 (de)
NZ (1) NZ579208A (de)
PE (2) PE20100448A1 (de)
PL (2) PL1781802T3 (de)
PT (2) PT1992697E (de)
RS (2) RS51072B (de)
RU (1) RU2458988C2 (de)
SI (2) SI1992697T1 (de)
SV (1) SV2006002211A (de)
TW (1) TWI364458B (de)
UA (1) UA89383C2 (de)
WO (1) WO2006026447A2 (de)
ZA (1) ZA200701672B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
PE20070796A1 (es) * 2005-10-24 2007-08-15 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
US20070231895A1 (en) * 2005-11-02 2007-10-04 Lee Gene W Methods for adapting mammalian cells
WO2008008360A1 (en) * 2006-07-13 2008-01-17 Wyeth Production of glycoproteins
ES2541546T3 (es) * 2006-11-03 2015-07-21 Wyeth Llc Sustancias que inhiben la glucólisis en cultivo celular
CN104152395B (zh) * 2006-11-08 2020-03-10 惠氏公司 合理设计的细胞培养基
EP2115126B1 (de) * 2007-03-02 2015-04-08 Wyeth LLC Verwendung von kupfer und glutamat in zellkulturen zur herstellung von polypeptiden
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
JP5576115B2 (ja) 2007-04-26 2014-08-20 中外製薬株式会社 高濃度アミノ酸含有培地を用いた細胞の培養方法
DK2310523T3 (en) 2008-04-17 2015-07-20 Wyeth Llc Methods for increasing the production of bone morphogenetic proteins
CN102007207B (zh) * 2008-04-18 2012-05-30 上海抗体药物国家工程研究中心有限公司 一种浓缩培养液及其使用方法
WO2010016943A2 (en) * 2008-08-08 2010-02-11 Biogen Idec Ma Inc. Nutrient monitoring and feedback control for increased bioproduct production
ES2793348T3 (es) 2009-08-11 2020-11-13 Hoffmann La Roche Producción de proteínas en medios de cultivo celular libres de glutamina
RU2012127383A (ru) * 2009-12-02 2014-01-10 Акселерон Фарма Инк. Композиции и способы для увеличения времени полужизни fc-слитых белков в сыворотке
CA2795461C (en) 2010-04-26 2018-04-24 Novartis Ag Improved cell cultivation process
KR101848945B1 (ko) 2010-04-26 2018-04-16 노파르티스 아게 개선된 세포 배양 배지
JP2013535981A (ja) 2010-08-20 2013-09-19 ワイス・エルエルシー 成長因子不含適合細胞の細胞培養
EP2640483A1 (de) 2010-11-15 2013-09-25 Biogen Idec Inc. Aneicherung und konzentrierung ausgewählter produktisoformen durch überlastete bindung und elutionschromatographie
ES2560470T3 (es) 2011-04-29 2016-02-19 Biocon Research Limited Un método para reducir la heterogeneidad de anticuerpos y un proceso de producción de dichos anticuerpos
US8883982B2 (en) 2011-06-08 2014-11-11 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
BR112014009031A2 (pt) 2011-10-18 2017-05-09 Coherus Biosciences Inc formulações de etanercept estabilizadas com íons de metais
SG11201401220SA (en) * 2011-10-21 2014-07-30 Pfizer Addition of iron to improve cell culture
JP2015509714A (ja) * 2012-02-22 2015-04-02 エヌヴィーアイピー プロプライエタリー リミテッド 腫瘍壊死因子レセプター融合タンパク質及び前記タンパク質を使用する方法
KR20150030704A (ko) 2012-07-09 2015-03-20 코히러스 바이오사이언시즈, 인코포레이티드 육안으로 보이지 않는 입자의 현저한 감소를 나타내는 에타너셉트 제형
RS57013B1 (sr) 2012-09-11 2018-05-31 Coherus Biosciences Inc Korektno savijeni etanercept sa visokom čistoćom i odličnim prinosom
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
JP6689189B2 (ja) 2013-03-26 2020-04-28 コヒラス・バイオサイエンシズ・インコーポレイテッド タンパク質産生方法
KR101439195B1 (ko) 2013-04-18 2014-09-12 동아대학교 산학협력단 에셰리키아 콜리 a-53 균주를 이용하여 섬유소 분해효소의 생산성을 향상시키는 공정
DK3351620T3 (da) * 2013-10-11 2020-10-26 Regeneron Pharma Metabolsk optimeret cellekultur
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
EP3683316A1 (de) * 2014-01-30 2020-07-22 Coherus Biosciences, Inc. Perfusionsmedien
JP6609561B2 (ja) 2014-02-04 2019-11-20 バイオジェン・エムエイ・インコーポレイテッド 翻訳後修飾を濃縮するための、フロースルーモードにおける陽イオン交換クロマトグラフィーの使用
IL276165B (en) * 2014-12-01 2022-11-01 Amgen Inc A process for adjusting the glycan content level of a glycoprotein
KR102007930B1 (ko) 2014-12-31 2019-08-06 주식회사 엘지화학 재조합 당단백질의 글리코실화 조절 방법
CN105777897A (zh) * 2015-03-20 2016-07-20 广东东阳光药业有限公司 一种cho细胞收获液的前处理方法
SG11201705743YA (en) * 2015-04-01 2017-08-30 Boehringer Ingelheim Int Cell culture medium
KR101936049B1 (ko) * 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
MX2019004580A (es) 2016-10-21 2019-08-12 Amgen Inc Formulaciones farmaceuticas y metodos para prepararlas.
CN110484487A (zh) * 2019-08-21 2019-11-22 安徽欣乐生物技术有限公司 一种适用于cho细胞培养用无蛋白培养基及其培养方法
WO2022140389A1 (en) 2020-12-22 2022-06-30 Amgen Inc. Cell culture method
CN115073607A (zh) * 2021-03-12 2022-09-20 上海康岱生物医药技术股份有限公司 Tnfr2与baff受体的融合蛋白
CN114480492B (zh) * 2022-01-28 2023-04-21 景泽生物医药(合肥)股份有限公司 一种重组人抗体融合蛋白的制备方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5672502A (en) * 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0435911B1 (de) * 1988-09-23 1996-03-13 Cetus Oncology Corporation Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US6048728A (en) * 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US6291159B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
NZ235148A (en) * 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
JPH0396383A (ja) 1989-09-08 1991-04-22 Riso Kagaku Corp 画像形成装置
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
AU638762B2 (en) * 1989-10-05 1993-07-08 Optein Inc Cell-free synthesis and isolation of novel genes and polypeptides
US6657103B1 (en) * 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5538983A (en) * 1990-05-16 1996-07-23 The Rockefeller University Method of treating amyloidosis by modulation of calcium
US5156964A (en) * 1990-08-16 1992-10-20 Cetus Corporation Methods for adapting cells for increased product production through exposure to ammonia
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
GB2251249B (en) 1990-12-28 1995-06-21 Mogam Biotech Res Inst High-density medium for animal cell culture
GB9118664D0 (en) * 1991-08-30 1991-10-16 Celltech Ltd Cell culture
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
JP3504963B2 (ja) 1993-10-22 2004-03-08 智靖 羅 抗ヒト高親和性ＩｇＥ受容体モノクローナル抗体に係るアミノ酸配列をコードするＤＮＡ断片
US6310185B1 (en) * 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
US5856179A (en) * 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5589154A (en) * 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6656466B1 (en) * 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US5721121A (en) * 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
JP4306813B2 (ja) * 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US20020012991A1 (en) 1997-04-07 2002-01-31 Florence Chua Nee Ho Kit Fong Cell culture media for enhanced protein production
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
CA2354862A1 (en) 1998-10-19 2000-04-27 Yeda Research And Development Co. Ltd. Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
DE60229051D1 (de) 2001-04-30 2008-11-06 Lilly Co Eli Humanisierte antikörper
EP2165714B1 (de) 2001-04-30 2013-10-23 Eli Lilly And Company Humanisierte Antikörper die das Beta-Amyloid Peptid erkennen
EP1404813A4 (de) 2001-06-13 2004-11-24 Genentech Inc Verfahren zur kultivierung tierischer zellen und polypeptidproduktion in tierischen zellen
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
WO2003072714A2 (en) 2002-02-21 2003-09-04 Wyeth Follistatin domain containing proteins
KR20040094709A (ko) 2002-02-21 2004-11-10 와이어쓰 폴리스타틴 도메인을 포함하는 단백질
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
SI1507556T1 (sl) 2002-05-02 2016-10-28 Wyeth Holdings Llc Konjugati kaliheamicinski derivat-nosilec
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法

Also Published As

Publication number Publication date
CR20120560A (es) 2012-12-04
PT1992697E (pt) 2010-04-21
HN2005000485A (es) 2009-06-09
CL2017000577A1 (es) 2017-12-01
BRPI0514694B1 (pt) 2019-04-24
ZA200701672B (en) 2012-04-24
ES2335518T3 (es) 2010-03-29
IL181588A (en) 2010-12-30
JP2008511330A (ja) 2008-04-17
PT1781802E (pt) 2010-01-04
DK1992697T3 (da) 2010-05-17
MY137803A (en) 2009-03-31
IL181588A0 (en) 2007-07-04
KR100988451B1 (ko) 2010-10-18
HRP20100271T1 (hr) 2010-06-30
TW200619388A (en) 2006-06-16
ES2341390T3 (es) 2010-06-18
HK1099941A1 (en) 2007-08-31
RS51072B (sr) 2010-10-31
PE20060815A1 (es) 2006-09-14
DE602005017285D1 (de) 2009-12-03
NO344785B1 (no) 2020-04-27
JP5921910B2 (ja) 2016-05-24
EP1992697A1 (de) 2008-11-19
JP2016056214A (ja) 2016-04-21
CY1109721T1 (el) 2014-08-13
EP1992697B1 (de) 2010-03-17
HRP20100011T1 (hr) 2010-02-28
CA2578138A1 (en) 2006-03-09
KR20070069140A (ko) 2007-07-02
EP1781802B1 (de) 2009-10-21
SI1992697T1 (sl) 2010-07-30
SV2006002211A (es) 2006-10-04
AR050537A1 (es) 2006-11-01
US20060121569A1 (en) 2006-06-08
GT200500234A (es) 2006-10-10
EP1781802A2 (de) 2007-05-09
WO2006026447A9 (en) 2006-06-01
PL1781802T3 (pl) 2010-03-31
BRPI0514694B8 (pt) 2021-05-25
AU2005280036A1 (en) 2006-03-09
ECSP077354A (es) 2007-05-30
UA89383C2 (ru) 2010-01-25
DK1781802T3 (da) 2010-01-25
TWI364458B (en) 2012-05-21
ATE446376T1 (de) 2009-11-15
RU2007108717A (ru) 2008-10-10
CA2578138C (en) 2010-10-05
PE20100448A1 (es) 2010-06-22
WO2006026447A3 (en) 2006-04-20
ATE461285T1 (de) 2010-04-15
NZ579208A (en) 2012-01-12
NO20071570L (no) 2007-05-23
AR088824A2 (es) 2014-07-10
CY1110092T1 (el) 2015-01-14
BRPI0514694A (pt) 2008-06-17
SI1781802T1 (sl) 2010-01-29
CN102876761A (zh) 2013-01-16
AU2005280036B2 (en) 2011-11-03
GT200500233A (es) 2006-03-09
PL1992697T3 (pl) 2010-08-31
CR8998A (es) 2007-11-23
US7300773B2 (en) 2007-11-27
CN101061231A (zh) 2007-10-24
WO2006026447A2 (en) 2006-03-09
MX2007002381A (es) 2007-06-15
JP2012095672A (ja) 2012-05-24
HK1121497A1 (en) 2009-04-24
EG26922A (en) 2014-12-25
RS51255B (sr) 2010-12-31
RU2458988C2 (ru) 2012-08-20
CN101061231B (zh) 2012-09-26

Similar Documents

Publication Publication Date Title
ATE461285T1 (de) Herstellung von tnfr-fc
DE602005018076D1 (de) Enantioselektive herstellung von chinolin-derivaten
FI20041059A0 (fi) Komponentin sisältävän kerroksen valmistaminen
DE602005011285D1 (de) Formmasse von polymer
DE602007014179D1 (de) Herstellung von polytrimethylen-etherglykol
DE602006006861D1 (de) Herstellung von polytrimethylenetherglykol und copolymeren davon
DE602006006710D1 (de) Herstellung von polytrimethylenetherglykol und copolymeren davon
DE602004029836D1 (de) Herstellung von Turbinenelementen
DE602004013599D1 (de) Herstellung von somatostatinpeptiden
DE602004022046D1 (de) Herstellung von kleinen teilchen
DE602004003529D1 (de) Herstellung von Organohalosilanen
DE60307022D1 (de) Herstellung von Organohalosilanen
SE0601411L (sv) Förfarande vid beredning
FI20041385A (fi) Symmetria-akselin määrittäminen
DE602005026641D1 (de) Neue 1-methoxy-2-phenylethene zur herstellung von 5-carboxaldehyd-2,3-dihydrobenzoxepinen
SE0403090D0 (sv) Framställning av häften
ES1058948Y (es) Helice
DE502004006136D1 (de) Verrastung von Baugruppen
FI20041228A (fi) Hiomakiven kunto
FI20040640A0 (fi) Ruukku tai sen kaltainen
SE0403161D0 (sv) Ny användning av glucosine
DE602004009544D1 (de) Neue 3,3-Dimethyl-5-Cyano-Benzoxepinderivate verwendbar zur Herstellung von 5-Formyl-Benzoxepinderivaten
NO20042454D0 (no) Novel fish virus
FR2881023B1 (fr) Rotor d'andaineur
FI6132U1 (fi) Puukappaleiden liitos

Legal Events

Date Code Title Description
8363 Opposition against the patent
R082 Change of representative

Ref document number: 1992697

Country of ref document: EP

Representative=s name: REITSTOETTER, KINZEBACH & PARTNER (GBR), DE